Brevital Sodium 500 mg/vial for Injection Recall
Brevital Sodium 500 mg/vial for Injection
What does the FDA announcement say about status?
This FDA-published company announcement reports the recall and its instructions. It does not supply an FDA enforcement classification or a live recall-completion status. Follow the announcement and contact the firm for current guidance.
What is the scope of this recall record?
Use the official announcement to check the affected product identifiers and full scope.
This announcement was last checked on 2026-10-19. The company's announcement date, FDA publication date and this site's first observation are recorded separately.
Why was Brevital Sodium 500 mg/vial for Injection recalled?
Presence of particulate matter identified as cellulose
What should I do if I have this product?
Follow the company's instructions in the official FDA announcement.
What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.
Is my product affected?
Compare your product with the product description and available lot, UPC or model codes below from the official FDA record to check whether it is covered by this recall. If an identifier is missing or unclear, check the complete official notice or contact the firm; an incomplete match here does not establish that your product is unaffected.
Which lot codes, UPCs or models are affected?
Product | Size | Item Code | Lot Numbers Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP), Distributed by: Par Pharmaceutical* | 42023-105-01 | 86930 | 02/2028 Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP), Distributed by: Par Pharmaceutical* | 42023-105-01 | 88623 | 04/2028
- FDA announcement ID
- 430107
- Product
- Brevital Sodium 500 mg/vial for Injection
- Recalling firm
- Par Health
- FDA published
- October 9, 2026
- Company announced
- October 8, 2026
- First observed by this site
- October 15, 2026
- Agency
- FDA (drug)